Please Wait
Applying Filters...
menu
    • menu
    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Lanadelumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EMA approves Takhzyro for HAE patients 12+ year & above
    EMA approves Takhzyro for HAE patients 12+ year & above

    24 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-european-medicines-agency-ema-has-approved-an-additional-subcutaneous-administration-option-for-takhzyro-lanadelumab-for-patients-aged-12-years-and-above-with-recurrent-attacks-of-hereditary-angioedema-hae-302382239.html

    PR NEWSWIRE
    24 Feb 2025
    Share Share
    The European Commission Approves Label Update for TAKHZYRO
    The European Commission Approves Label Update for TAKHZYRO

    18 Nov 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-european-commission-approves-label-update-for-takhzyro-lanadelumab-expanding-its-use-to-a-broader-group-of-paediatric-patients-with-recurrent-attacks-of-hereditary-angioedema-hae-301992261.html

    PR NEWSWIRE
    18 Nov 2023
    Share Share
    Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab
    Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab

    22 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/takeda-receives-positive-chmp-opinion-recommending-approval-of-lanadelumab-for-routine-prevention-of-recurrent-attacks-of-hereditary-angioedema-hae-in-patients-aged-2-years-and-older-301936251.html

    PR NEWSWIRE
    22 Sep 2023
    Share Share
    Takeda to Present SPRING Study of TAKHZYRO in Pediatric Patients With HAE
    Takeda to Present SPRING Study of TAKHZYRO in Pediatric Patients With HAE

    13 Feb 2023

    // PRESS RELEASE

    https://www.takeda.com/newsroom/newsreleases/2023/takeda-to-present-multiple-new-data-analyses-at-2023-aaaai-annual-meeting-including-spring-study-of-takhzyro-in-pediatric-patients-with-hereditary-angioedema-hae/

    PRESS RELEASE
    13 Feb 2023
    Share Share
    U.S. FDA Approves Takeda’s TAKHZYRO to Prevent HAE Attacks
    U.S. FDA Approves Takeda’s TAKHZYRO to Prevent HAE Attacks

    04 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230203005431/en

    BUSINESSWIRE
    04 Feb 2023
    Share Share
    U.S. FDA Accepts Takeda’s Supplemental BLA for Use of TAKHZYRO
    U.S. FDA Accepts Takeda’s Supplemental BLA for Use of TAKHZYRO

    05 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221004006135/en

    BUSINESSWIRE
    05 Oct 2022
    Share Share